Ipr patent expiration

1. Crestor patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE37314 IPR Pyrimidine derivatives
Jan, 2016

(8 years ago)

USRE37314

(Pediatric)

IPR Pyrimidine derivatives
Jul, 2016

(8 years ago)

US7964614 IPR Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Apr, 2018

(6 years ago)

US7030152 IPR Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Apr, 2018

(6 years ago)

US7964614

(Pediatric)

IPR Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Oct, 2018

(5 years ago)

US7030152

(Pediatric)

IPR Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
Oct, 2018

(5 years ago)

US6316460 IPR Pharmaceutical compositions
Aug, 2020

(3 years ago)

US6316460

(Pediatric)

IPR Pharmaceutical compositions
Feb, 2021

(3 years ago)

US6858618 IPR Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Dec, 2021

(2 years ago)

US6858618

(Pediatric)

IPR Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
Jun, 2022

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-573) Nov 06, 2011
New Indication(I-611) Oct 16, 2012
New Indication(I-621) Feb 08, 2013
Pediatric Exclusivity(PED) Apr 16, 2013
New Patient Population(NPP) Nov 20, 2018
New Indication(I-732) May 27, 2019
Orphan Drug Exclusivity(ODE-118) May 27, 2023
Orphan Drug Exclusivity(ODE) May 27, 2023

Drugs and Companies using ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 12 August, 2003

Treatment: Use of rosuvastatin calcium for the primary prevention of cardiovascular disease in individuals without clinically evident coronary heart disease but with increased risk factors; Use of rosuvastatin c...

Dosage: TABLET

How can I launch a generic of CRESTOR before it's drug patent expiration?
More Information on Dosage

CRESTOR family patents

Family Patents

2. Zomig patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5466699 IPR Indolyl compounds for treating migraine
Nov, 2012

(11 years ago)

US5863935 IPR Therapeutic heterocyclic compounds
Nov, 2012

(11 years ago)

US5466699

(Pediatric)

IPR Indolyl compounds for treating migraine
May, 2013

(11 years ago)

US5863935

(Pediatric)

IPR Therapeutic heterocyclic compounds
May, 2013

(11 years ago)




Drugs and Companies using ZOLMITRIPTAN ingredient

Market Authorisation Date: 25 November, 1997

Treatment: NA

Dosage: TABLET

How can I launch a generic of ZOMIG before it's drug patent expiration?
More Information on Dosage

ZOMIG family patents

Family Patents